CUVITRU is a subcutaneous immunoglobulin (SCIG) therapy used for the treatment of primary immunodeficiency (PI) in patients two years of age and older. Primary immunodeficiency diseases are a group of disorders that occur due to the immune system's inability to function properly, leaving individuals more susceptible to infections. CUVITRU contains immunoglobulin G (IgG), which is a type of antibody that plays a crucial role in the immune response by recognizing and neutralizing pathogens such as bacteria and viruses. Administered under the skin, CUVITRU provides a flexible and convenient option for patients, allowing for the possibility of self-administration at home after proper training. This medication is designed to boost the immune system by providing the necessary antibodies that the patient's body cannot produce sufficiently, thereby reducing the frequency of infections and improving the quality of life for individuals with PI.